OM Outset Medical

Outset Medical Names Derick Elliott as Executive Vice President of Commercial

Outset Medical Names Derick Elliott as Executive Vice President of Commercial

SAN JOSE, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today announced the appointment of Derick Elliott as Executive Vice President of Commercial, effective immediately.

Mr. Elliott is responsible for Outset’s commercial organizations supporting acute, post-acute and home healthcare providers, reporting to Chair and CEO Leslie Trigg. He joins Outset with more than 30 years of sales and marketing experience from Stryker, Cardinal Health and most recently SpendMend, a private company where he successfully drove a commercial strategy similar to Outset’s, leveraging a software, technology and services platform to change practice and help acute-care providers realize clinical, financial and operational benefits.

“Derick joins Outset at an ideal time as we expand our differentiated offering with new technology and services, and build on an already established base of clinical, operational and financial evidence to help acute and post-acute care providers realize the enormous benefits of insourcing dialysis with Outset and Tablo,” said Ms. Trigg. “He brings a strong track record of commercial strategy and execution across capital equipment, software, EMR connectivity and other recurring revenue streams, including partnering with health systems to create new service lines and optimize their operations. His broad and deep relationships with leading U.S. healthcare providers will serve us well as we continue to build on the nearly 1,000 acute facilities now using Tablo.”

Prior to joining Outset, Mr. Elliott served as Chief Commercial Officer of SpendMend. He previously served in sales and marketing roles of increasing responsibility for 17 years at Stryker, most recently as Vice President of Customer Solutions. Earlier in his career, he spent more than 10 years in sales and marketing roles in the Medical Products segment of Cardinal Health. He earned his MBA from the Kellogg School of Management at Northwestern University and Bachelor of Science degree in Business Administration with a concentration in finance from the University of Colorado Boulder.

“I have been impressed with the Outset management team, board and marquee roster of customers using Tablo to insource dialysis,” said Mr. Elliott. “This is a motivated team with a highly differentiated solution in one of the largest corners of healthcare. I am excited by the opportunity to help the company deliver the benefits of insourcing to an even broader set of customers and ultimately enable clinicians to improve the lives of the patients they serve.”

About Outset Medical, Inc.

Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visit .

Investor Contact

Jim Mazzola



EN
06/04/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Outset Medical

 PRESS RELEASE

Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635...

Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN JOSE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company’s Inducement Plan, as a material inducement to employment to Derick Elliott, the Company’s newly appointed Executive Vice President of Commercial, as well a...

 PRESS RELEASE

Outset Medical Names Derick Elliott as Executive Vice President of Com...

Outset Medical Names Derick Elliott as Executive Vice President of Commercial SAN JOSE, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today announced the appointment of Derick Elliott as Executive Vice President of Commercial, effective immediately. Mr. Elliott is responsible for Outset’s commercial organizations supporting acute, post-acute and home healthcare providers, reporting to Chair and CEO Leslie Trigg. He ...

 PRESS RELEASE

Outset Medical Reports Fourth Quarter and Full Year 2025 Financial Res...

Outset Medical Reports Fourth Quarter and Full Year 2025 Financial Results SAN JOSE, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter, Year-End and Recent Highlights Net revenue totaled $28.9 million in the fourth quarter, bringing revenue in 2025 to $119.5 million, a 5% increase over $113.7 million in 2024.Recurring revenu...

 PRESS RELEASE

Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Seco...

Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Second Quarter Launch Planned Tablo becomes first dialysis system to clear FDA’s most rigorous cybersecurity standards SAN JOSE, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) of its next-generation Tablo platform, designed to deliver enterprise-level security, reliability ...

 PRESS RELEASE

Outset Medical to Report Fourth Quarter 2025 Financial Results on Wedn...

Outset Medical to Report Fourth Quarter 2025 Financial Results on Wednesday, February 11, 2026 SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2025 after the close of trading on Wednesday, February 11, 2026. On the same day, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Rene...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch